[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595724":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":11,"locations":27,"responsibleParty":46,"collaborators":11,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":11,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":11,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":11,"overallStatus":30,"whyStopped":11,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HDM1702","EXPERIMENTAL",null,[13],"Drug: HDM1702",{"label":15,"type":16,"description":11,"interventionNames":17},"WEGOVY®","ACTIVE_COMPARATOR",[18],"Drug: Wegovy ®",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","Initiate at a once weekly dose of 0.25 mg and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg per week) aiming at reaching the maintenance dose of 2.4 mg at week 16.",[9],{"type":21,"name":25,"description":22,"armGroupLabels":26,"otherNames":11},"Wegovy ®",[15],[28],{"facility":29,"status":30,"city":31,"state":11,"zip":11,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Peking University People's Hospital","RECRUITING","Beijing","China","CN",{"type":35,"coordinates":36},"Point",[37,38],116.39723,39.9075,{"lat":38,"lon":37},[41],{"name":42,"role":43,"phone":44,"phoneExt":11,"email":45},"Linong Ji, Medical Doctor","CONTACT","+8601088324516","jiln@bjmu.edu.cn",{"type":47,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100595724","phase-3-efficacy-and-safety-of-semaglutide-injection-vs-wegovy-in-chinese-obese-patients-100595724",false,"NCT07036172","Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients","A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Clinical Study Comparing the Efficacy and Safety of Semaglutide Injection and WEGOVY® in Chinese Obese Patients","Inclusion Criteria:\n\n1. Male or female, aged ≥18 years and ≤75 years at the time of signing informed consent；\n2. BMI ≥28 kg\u002Fm2；\n3. A self-reported change in body weight no more than 5% within 90 days before screening.\n\nExclusion Criteria:\n\n1. History of type 1 and type 2 diabetes;\n2. Previous or planned (during the trial period) obesity treatment with surgery or a weight-loss device;\n3. History or presence of chronic or acute pancreatitis;\n4. Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma;\n5. A history or presence of suspected depression or other mental disorders;\n6. Patient Health Questionnaire-9 score of ≥15 at screening\n7. Uncontrolled hypertension, any of the following: myocardial infarction, stroke, hospitalisation for unstable angina, or transient ischaemic attack within the past 6 months prior to screening;\n8. History of malignant neoplasms within the past 5 years prior to screening;","ALL","18 Years","75 Years",{"count":59,"type":60},460,"ESTIMATED","INTERVENTIONAL",[63],"PHASE3","This is a 48-week randomized, open-label, parallel-controlled biosimilar comparison study comparing the efficacy, safety and immunogenicity of the investigational drug and WEGOVY® in patients with obesity. Eligible participants will be screened and randomized to the experimental group and the active comparator group at a ratio of 1:1 , semaglutide injection or WEGOVY® injection will be given once weekly for 44 weeks, following by a safety follow up of 4 weeks. All participants received a lifestyle intervention that involved counselling on diet and physical activity.",[66],"Obesity Control","2025-06-16",{"date":69,"type":70},"2025-06-25","ACTUAL",{"date":72,"type":70},"2025-01-03",{"date":74,"type":60},"2026-05",{"name":5,"class":6},1]